Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › mepolizumab

mepolizumab

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of mepolizumab

31 trials tracked of mepolizumab: 22 in phase 3 or 4 and 15 with published results. The most-cited published study has 1047 citations.

31Trials tracked
22Phase 3 & 4
0Recruiting
15With published results
Phase distribution
Phase 4 3 Phase 3 19 Phase 2 6 Phase 1 1 Other / NA 2
  1. Phase 3 A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Completed · 1,047 cited
  2. Phase 3 Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD) Completed · 587 cited
  3. Phase 3 Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients Completed · 587 cited
  4. Phase 3 MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects Completed · 297 cited
  5. Phase 3 A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Completed · 165 cited
  6. Phase 3 Effect of Mepolizumab in Severe Bilateral Nasal Polyps Completed · 121 cited
Show 25 more trials
  1. Phase 3 Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Completed · 105 cited
  2. Phase 3 Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis Completed · 75 cited
  3. Phase 3 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed · 55 cited
  4. Phase 3 A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 Completed · 44 cited
  5. Phase 3 Study of Mepolizumab Safety Syringe in Asthmatics Completed · 34 cited
  6. Phase 3 Study of Mepolizumab Autoinjector in Asthmatics Completed · 27 cited
  7. Phase 3 A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Completed · 27 cited
  8. Phase 3 Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Completed · 13 cited
  9. Phase 4 Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab) Completed · 2 cited
  10. Phase 4 Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma Completed
  11. Phase 4 Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases Completed
  12. Phase 3 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Completed
  13. Phase 3 Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS) Completed
  14. Phase 3 Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) Completed
  15. Phase 3 Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma Completed
  16. Phase 3 A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects Completed
  17. Phase 2 Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Completed
  18. Phase 2 Mepolizumab in Nasal Polyposis Completed
  19. Phase 2 Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils Completed
  20. Phase 2 Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children Completed
  21. Phase 2 Intravenous Mepolizumab In Children With Eosinophilic Esophagitis Completed
  22. Phase 2 A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children Completed
  23. Phase 1 Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists Completed
  24. N/A Impulse Oscillometry Measurements in Severe Eosinophilic Asthmatics Before and After Anti-IL-5 Factor Initiation Completed
  25. N/A Eosinophilic Airway Inflammation and Mepolizumab Completed

Showing the 31 most-cited and recently-updated of 31 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies
Allergy & Immunology Meta-analysis
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies Switching Asthma Drugs Could Change Your Life
A systematic review and meta-analysis of 2,292 patients found that switching biologics significantly reduced exacerbations and improved asth…
If your severe asthma medication stops working, switching to a different biologic drug could cut your attacks in half and help you breathe e…
May 5, 2026
Meta-analysis shows biologic therapies reduce annual exacerbations in COPD patients with high eosinophils while maintaining safety profiles
Pulmonology & Critical Care Meta-analysis
Meta-analysis shows biologic therapies reduce annual exacerbations in COPD patients with high eosinophils while maintaining safety profiles New drugs cut COPD flare-ups for patients with high eosinophils
This living evidence synthesis evaluates dupilumab and mepolizumab in 7,359 COPD patients. Results indicate reduced annual exacerbation rate…
New biologic drugs lower the yearly number of COPD flare-ups for patients with high eosinophil counts while keeping side effects low
May 3, 2026
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases
Allergy & Immunology Sys. Review
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases New Asthma Drugs Target the Real Troublemakers Hiding in Your Lungs
This systematic review examined the use of anti-IL-5 and anti-IL-5Rα biologics in patients with severe eosinophilic asthma, chronic rhinosin…
New asthma drugs target the specific immune cells causing swelling and mucus in severe asthma, nasal polyps, and rare eosinophil diseases.
Frontiers Apr 16, 2026
Systematic review examines IL-5-targeted and multi-target therapies for eosinophil-associated diseases including asthma and COPD
Oncology Sys. Review
Systematic review examines IL-5-targeted and multi-target therapies for eosinophil-associated diseases including asthma and COPD A Tricky Immune Messenger Behind Severe Asthma
This systematic review evaluated IL-5-targeted therapies, multi-target combination therapies, bispecific antibodies, and small-molecule inhi…
A protein called IL-5 fuels severe asthma, but new drugs targeting multiple immune pathways at once may finally help patients who haven't re…
Frontiers Apr 14, 2026
Mepolizumab plus FESS improved lung function and symptoms versus mepolizumab alone in severe CRSwNP
Allergy & Immunology RCT
Mepolizumab plus FESS improved lung function and symptoms versus mepolizumab alone in severe CRSwNP When Your Nose and Lungs Are Fighting the Same War
This single randomized controlled trial enrolled 58 patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) with or without a…
A biologic drug improves both sinus and lung symptoms in people with severe nasal polyps, and adding surgery helps the nose more but doesn't…
Apr 10, 2026
Mepolizumab fails to improve refractory chronic cough in small eosinophilic airways disease trial
Allergy & Immunology RCT
Mepolizumab fails to improve refractory chronic cough in small eosinophilic airways disease trial Mepolizumab reduced inflammation but did not improve cough in a small study
A single-centre randomised controlled trial of 30 patients with refractory chronic cough and eosinophilic airways disease found subcutaneous…
Mepolizumab lowered inflammation markers in patients with chronic cough but failed to reduce their coughing or improve their quality of life…
Apr 9, 2026